Return to: Medical School : Academic Health Center : myU : U of M Home

Gold University of Minnesota M. Skip to main content. Link to University of Minnesota homepage
Obstetrics, Gynecology, and Womens Health
Whats Inside
Clinical Services

Directory

Education

News and Events

Programs

Research

 

OBGYN Home

Make a gift to Medicine

Home > Directory > Gynecologic Oncology > Levi Downs, M.D., M.S., F.A.C.O.G.

Printer-friendly version   Mail this page to a friend

Levi Downs, M.D., M.S., F.A.C.O.G.


Dr. Levi Downs, Jr.

downs008@umn.edu
612-626-3111, office
Dr. Downs' clinical profile
(University of Minnesota Physicians Web site)

Dr. Downs is an Assistant Professor in the Department of Obstetrics, Gynecology and Women’s Health and is the Interim Director of the Division of Gynecologic Oncology.  In addition, Dr. Downs is the Clinical Care Co-Director of the Deborah. E. Powell Center for Women's Health, A Nationally Designated Center of Excellence an is the Program Co-leader of the Women's Cancer Research Program.  Dr. Downs is a board certified gynecologic oncologist.

Dr. Downs received his medical degree in 1994 from the University of Pittsburgh School of Medicine and completed an obstetrics and gynecology internship and residency at the Magee-Women’s Hospital of the University of Pittsburgh Medical Center.  He completed a gynecologic oncology fellowship at the University of Minnesota.

Dr. Downs’ research interests include HPV induced carcinogenesis, molecular therapeutics for cervical cancer and gynecologic oncology clinical trials.

Thank you to Turner Biosystems Luminometer Grants Program for their generous donation of a luminometer: http://www.luminometer.org

Selected Publications

Downs LS Jr, Lima PH, Bliss RL, Blomquist CH.  Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.  J Soc Gynecol Investig. 2005;12(7):539-44.

Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, Dusenbery K, Downs LS Jr.  Clinical features and outcomes of uterine and ovarian carcinosarcoma.  Gynecol Oncol. 2006;100(3):561-4.

Chura JC, Brooker D, Downs LS Jr.  Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma.  Case report and review of the literature.  Gynecol Oncol. 2006;103(1):336-41.

Argenta PA, Ghebre R, Dusenbery KE, Chen MD, Judson PL, Downs LS Jr, Carson LF.  Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer:  Long-term follow-up.  Eur J Gynaecol Oncol. 2006;27(3):231-5.

Chura JC, Truskinovsky AM, Judson PL, Johnson L, Geller MA, Downs LS Jr.  Positron emission tomography and leiomyomas:  Clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature review.  Gynecol Oncol. 2007;104(1):247-52.

Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL.  Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.  Gynecol Oncol. 2007;107(2):326-30.

Chura JC, Downs LS Jr.  Positron emission tomography and uterine leiomyomas:  Authors' response.  Gynecol Oncol. 2007; Oct 23 [Epub ahead of print]

Bradley WH, Lima PH, Rodgers L, Blomquist CH, Downs LS.  Endometrial carcinoma expresses an increased cathepsin B/D ratio.  Gynecol Oncol. 2008;108(1):84-9.

Downs LS Jr, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, Nahhas WA, Abu-Ghazaleh SZ, Chen MD, Carson LF.  A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.  Cancer 2008;112(2):331-9.

Clinics:


Feedback | Notice of Privacy Practices


 
The University of Minnesota is an equal opportunity educator and employer.